butyl-[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-ethyl-amine

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: butyl-[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-ethyl-amine
• 英文别名: N-butyl-N-ethyl-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)pyridin-4-amine
• 化学式: C₂₂H₃₂N₂O
• 分子量: 340.509
• InChiKey: SAUITORPTLSQEO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  25.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• New uses for corticotropin releasing factor (CRF) antagonists
  申请人：PFIZER INC.

  公开号：EP0773023A1

  公开（公告）日：1997-05-14

  A method of treating, preventing or inhibiting a disorder selected from the group consisting of cardiovascular or heart related diseases such as stroke, hypertension, tachycardia, and congestive heart failure, osteoporosis, premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus, and colonic hypersensitivity associated with psychopathological disturbance and stress, comprising administering to a mammal, including a human, in need of such treatment a therapeutically effective amount of a compound of the formula    or a pharmaceutically acceptable salt thereof, wherein A, B, D, E, Y, Z, R3, R4, and R5 are as defined herein.

  一种治疗、预防或抑制心血管或心脏相关疾病（如中风、高血压、心动过速和充血性心力衰竭）、骨质疏松症、早产、心理社交侏儒症、压力诱发发热、溃疡、腹泻、术后肠梗阻和与心理病理障碍和压力相关的结肠过敏反应的方法，包括向需要此类治疗的哺乳动物（包括人类）中，给予化合物的治疗有效量，该化合物的结构式如下：其中A、B、D、E、Y、Z、R3、R4和R5的定义如本文所述，或其药学上可接受的盐。
• New uses for corticotropin releasing factor antagonists
  申请人：——

  公开号：US20010000340A1

  公开（公告）日：2001-04-19

  A method of treating, preventing or inhibiting a disorder selected from the group consisting of cardiovascular or heart related diseases such as stroke, hypertension, tachycardia, and congestive heart failure, osteoporosis, premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus, and colonic hypersensitivity associated with psychopathological disturbance and stress, comprising administering to a mammal, including a human, in need of such treatment a therapeutically effective amount of a compound of the formula 1 or pharmaceutically acceptable salt thereof, wherein A, B, D, E, Y, Z, R 3 , R 4 , and R 5 are as defined herein.

  一种治疗、预防或抑制选自心血管或心脏相关疾病（如中风、高血压、心动过速和充血性心力衰竭）、骨质疏松症、早产、心理社交侏儒症、应激性发热、溃疡、腹泻、术后肠梗阻和与心理病理障碍和应激有关的结肠过敏反应的方法，包括向需要该治疗的哺乳动物，包括人类，投与化合物1或其药学上可接受的盐的治疗有效量，其中A、B、D、E、Y、Z、R3、R4和R5如本文所定义。
• [EN] CORTICOTROPIN RELEASING FACTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU FACTEUR LIBERANT LA CORTICOTROPHINE
  申请人：PFIZER INC.

  公开号：WO1995033750A1

  公开（公告）日：1995-12-14

  (EN) Corticotropin-releasing factor (CRF) antagonists having formulae (I), (II) or (III) wherein the dashed lines, A, B, Y, Z, G, R3, R4, R5, R6, R16 and R17 are as defined in the description, and processes for preparing them. These compounds and their pharmaceutically acceptable salts are useful in the treatment of CNS and stress-related disorders.(FR) L'invention se rapporte à des antagonistes du facteur libérant la corticotrophine ayant les formules (I), (II) ou (III) dans lesquelles les lignes pointillées, A, B, Y, Z, G, R3, R4, R5, R6, R16 et R17 sont telles que définies dans la demande, et à leurs procédés de préparation. Ces composés et leurs sels pharmaceutiquement acceptables sont utilisés dans le traitement des troubles du système nerveux central (SNC) et des troubles relatifs au stress.

  Corticotropin-releasing factor (CRF)的拮抗剂具有式(I)、(II)或(III)，其中虚线、A、B、Y、Z、G、R3、R4、R5、R6、R16和R17的定义如说明书所述，并提供了制备它们的方法。这些化合物及其药学上可接受的盐在治疗中枢神经系统和与压力相关的疾病中有用。
• Corticotropin releasing factor antagonists
  申请人：Chen L. Yuhpyng

  公开号：US20050032846A1

  公开（公告）日：2005-02-10

  A pharmaceutical composition for treatment of a disorder or condition the treatment of which can be effected or facilitated by antagonizing Corticotropin Releasing Factor (CRF). The pharmaceutical composition includes a pharmaceutically acceptable carrier and an effective amount to treat the disorder or condition of the following compound: or a pharmaceutically acceptable salt thereof, wherein A, B, Z, R 3 , R 4 , and R 5 are as defined herein.

  一种用于治疗可以通过拮抗促肾上腺皮质激素释放因子（CRF）来治疗或促进治疗的疾病或病状的药物组合物。该药物组合物包括一种药用载体和以下化合物的有效治疗剂量或其药用可接受盐：或其药用可接受盐，其中A、B、Z、R3、R4和R5如本文所定义。
• Combinations of CRF antagonists and renin-angiotensin system inhibitors
  申请人：Pfizer Products Inc.

  公开号：EP1059100A2

  公开（公告）日：2000-12-13

  The present invention relates to compositions and methods of achieving a therapeutic effect including, but not limited to, the treatment of congestive heart failure or hypertension in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist and a renin-angiotensin system (RAS) inhibitor.

  本发明涉及使用促肾上腺皮质激素释放因子（CRF）拮抗剂和肾素-血管紧张素系统（RAS）抑制剂达到治疗效果的组合物和方法，治疗效果包括但不限于动物（最好是哺乳动物，包括人类或伴侣动物）的充血性心力衰竭或高血压。